Tadalafil and Acetazolamide Versus Acetazolamide for the Prevention of Severe High‐Altitude Illness: Table 1

Leshem, Eyal; Caine, Yehezkel; Rosenberg, Elliot; Maaravi, Yoram; Hermesh, Hagai; Schwartz, Eli

doi:10.1111/j.1708-8305.2012.00636.x

Cited by 18 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…with 10 mg of tadalafil has been shown to protect against HAPE (reducing incidence by 78%) in those who are susceptible by attenuating rises in PAP [118]. Newer research is in agreement with these earlier works demonstrating reductions in the incidence of HAPE with tadalafil [119].…”

Section: Phosphodiesterase Inhibitors (Pde-5 Inhibitors)supporting

confidence: 69%

“…Sildenafil may be appropriate for AMS and HACE prophylaxis based on its ability to increase cerebral oxygenation [120]. Tadalafil may have the potential to reduce cerebral specific AMS scores; however, it may also increase the potential of headache [111,119,121,122]. Consequently, more research is needed to clarify whether PDE-5 inhibitors can be used to prevent and treat AMS an HACE.…”

Section: Phosphodiesterase Inhibitors (Pde-5 Inhibitors)mentioning

confidence: 99%

See 1 more Smart Citation

Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema

Joyce

Lucas

Imray

et al. 2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Phosphodiesterase Inhibitors (Pde-5 Inhibitors)supporting

confidence: 69%

Section: Phosphodiesterase Inhibitors (Pde-5 Inhibitors)mentioning

confidence: 99%

Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema

Joyce

Lucas

Imray

et al. 2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Tadalafil once daily was found to improved exercise capacity and reduced time to clinical worsening in patients suffering from pulmonary arterial hypertension (PAH); offering an alternative to Sildenafil as well [21]. Finally, combining tadalafil with acetazolamide, rather than taking acetazolamide alone, can be an even more effective method for the prevention of some conditions [22]. Dosing of sildenafil is less restrictive in cases of compromised renal function.…”

Section: Broader Implicationsmentioning

confidence: 99%

Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19

Solaimanzadeh¹

2020

Cureus

View full text Add to dashboard Cite

Dihydropyridine calcium channel blockers (CCB) are typically used agents in the clinical management of hypertension. Yet, they have also been utilized in the treatment of various pulmonary disorders with vasoconstriction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been implicated in the development of vasoconstrictive, proinflammatory, and pro-oxidative effects. A retrospective review was conducted on CCB use in hospitalized patients in search of any difference in outcomes related to specific endpoints: survival to discharge and progression of disease leading to intubation and mechanical ventilation. The electronic medical records for all patients that tested positive for SARS-CoV-2 that were at or above the age of 65 and that expired or survived to discharge from a community hospital in Brooklyn, NY, between the start of the public health crisis due to the viral disease up until April 13, 2020, were included.

show abstract

“…Epidemiological studies have been conducted in the Himalayas (Basnyat et al, 2000;Vardy et al, 2006), the Alps (Mairer et al, 2009(Mairer et al, , 2010, the Rocky Mountains (Honigman et al, 1993), Mt. Kilimanjaro (Leshem et al, 2012), and Mt. Fuji (Horiuchi et al, 2016) on the association between the prevalence of AMS and relevant factors.…”

mentioning

confidence: 99%

Impact of Sleeping Altitude on Symptoms of Acute Mountain Sickness on Mt. Fuji

Horiuchi

Uno

Endo

et al. 2018

High Altitude Medicine & Biology

View full text Add to dashboard Cite

Horiuchi, Masahiro, Tadashi Uno, Junko Endo, Yoko Handa, and Tatsuya Hasegawa. Impact of sleeping altitude on symptoms of acute mountain sickness on Mt. Fuji. High Alt Med Biol. 19:193-200, 2018. Aims: We sought to investigate the factors influencing acute mountain sickness (AMS) on Mt. Fuji in Japan, in particular, to assess the effects of sleeping altitude, by means of a questionnaire survey. This study involved 1932 participants who climbed Mt. Fuji, and obtained information regarding sex, age, and whether participants stayed at the mountain lodges. The AMS survey excluded the perceived sleep difficulties assessed with the Lake Louise Scoring (LLS) system for all climbers. Results: The overall prevalence of AMS was 31.6% for all participants (LLS score ‡3 with headache, excluding sleep difficulties). A univariate analysis revealed that overnight stay at Mt. Fuji was associated with an increased prevalence of AMS, but that sex and age were not. For overnight lodgers, the mean sleeping altitude in participants with AMS was slightly higher than that in participants without AMS ( p < 0.05). Moreover, participants who stayed above 2870 m were more likely to experience AMS than those who stayed below 2815 m ( p < 0.001), but sex and age were not significantly associated with the probability of experiencing AMS. Conclusions: Staying overnight at a mountain lodge, especially one above 2870 m, may be associated with an increased prevalence of AMS on Mt. Fuji.

show abstract

Tadalafil and Acetazolamide Versus Acetazolamide for the Prevention of Severe High‐Altitude Illness: Table 1

Cited by 18 publications

References 8 publications

Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema

Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema

Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19

Impact of Sleeping Altitude on Symptoms of Acute Mountain Sickness on Mt. Fuji

Contact Info

Product

Resources

About